Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00790673 | A Phase 1/2 Study of CF102 in Patients With Chronic Hepatitis C Genotype 1 | PHASE1 | COMPLETED | 32 | — | — | Jul 1, 2009 | Jul 1, 2011 | Apr 15, 2015 | 1 | Israel |
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | CF102 1 mg qd |
| 2 | EXPERIMENTAL | CF102 1 mg bid |
| 3 | EXPERIMENTAL | CF102 1 mg bid; 16 weeks |
| 5 | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| CF 102 | DRUG | Oral capsules |
| Placebo | DRUG | Matching placebo capsules |
Inclusion Criteria: 1. 18 to 60 years of age 2. Body mass index ≤ 30 kg/m2 3. Either: 1. no evidence of cirrhosis, or liver fibrosis corresponding to Metavir Stages 0 to 31 on a liver biopsy performed within the past 2 years, or 2. a score of F0 or F1 on ActiTest-FibroTest performed within t...